The goal of this agreement is to incorporate SINTX AP2 silicon nitride powder into polymer materials.
These materials will become safe and effective surfaces for IT devices such as cases for cell phones and tablets that are touched frequently.
SINTX and Iwatani aim to create surfaces that resist bacteria and viruses.
The development of these products may help prevent and reduce the spread of respiratory diseases like SARS-CoV-2, Influenza A, and H1N1 by inactivating viruses and bacteria on the polymer surfaces.
SINTX and Iwatani intend to capitalize on recent and promising data demonstrating the potential of SINTX AP2silicon nitride powder to inactivate the SARS-CoV-2 virus that is responsible for the global COVID-19 pandemic.
Studies showing the rapid inactivation of SARS-CoV-2 by SINTX's silicon nitride are the latest in a series of papers showing similar activity of silicon nitride against a variety of bacteria and viral strains, the companies said.
SINTX and Iwatani plan to jointly fund collaborative product development activities in Salt Lake City, Utah, and Japan with the support of external laboratories as well.
SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications.
The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners.
The company presently manufactures silicon nitride powders and components in its FDA registered, AS9100D certified, and ISO 13485:2016 certified manufacturing facility.
Advita Ortho updates Chime clinical exchange application
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems
Realheart secures European patent for artificial heart technology
Median Technologies secures FDA clearance for AI lung cancer screening software
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Zylox-Tonbridge agrees staged acquisition of Germany's Optimed
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
Boston Scientific to acquire Valencia Technologies to expand overactive bladder portfolio